It was reported to boston scientific corporation that an expect¿ needle device was used in the tail of pancreas during an endoscopic ultrasound fine needle aspiration (eus fna) procedure performed on (b)(6) 2014 as part of the e7084 eus fna cystic lesions clinical study.
The patient had a history of diabetes.
The patient¿s pancreatic cystic lesion (pcl) was located in the tail of the pancreas and was not symptomatic.
The pcl was unilocular and had a maximal diameter of 15mm and a perpendicular measurement of 12mm.
The pcl was connected to the pancreatic duct.
There were no solid components, no presence of visible mucin, and no distinct pcl wall.
The maximal pancreatic duct diameter size was 23mm and a mural nodule was not present.
On (b)(6) 2014, the patient underwent eus fna.
Prophylactic antibiotics were given and the route of access of the echoendoscope was gastric.
During the procedure, the pcl could be reached and penetrated.
One pass was attempted and was successful, and no salvage procedure was required.
The total volume of aspirate was 2ml.
The aspirate¿s viscosity was like water, the clarity was clear, the color was transparent.
Per the eus fna, the disease was determined to be intraductal papillary mucinous neoplasm (ipmn).
On (b)(6) 2014, the patient presented with acute pancreatitis and was admitted to the hospital.
The patient was discharged on (b)(6) 2014.
According to the physician, the patient had undergone a separate fna from a transitional zone in the main pancreatic duct of the pancreas.
Per the physician, fnas of the main duct carry higher risk of pancreatitis.
Therefore, the physician was unable to determine with 100% certainty whether the pancreatitis was due to the cyst fna with the expect needle or due to the other fna of the main duct.
|